You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

Drug Price Trends for NDC 00713-0555


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00713-0555

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00713-0555

Last updated: September 20, 2025


Introduction

NDC 00713-0555 identifies a specific pharmaceutical product within the U.S. drug pricing and distribution framework, overseen by the National Drug Code (NDC) system. This analysis examines current market dynamics, competitive landscape, and future price trajectories associated with this product.


Product Overview and Therapeutic Landscape

NDC 00713-0555 corresponds to [Insert specific drug name, formulation, and primary indication], a medication indicated for [indication, e.g., oncology, cardiology, neurology]. The drug's formulation, administration route, and approved positioning significantly influence its market penetration and pricing strategies.

The drug operates within a competitive sphere where therapies with similar mechanisms vie for market share. Recent advances in biosimilars or generics could challenge the brand product’s pricing and exclusivity status. Key therapeutic competitors include [list competitors] and alternative treatment modalities.


Market Size and Demand Dynamics

Market demand for NDC 00713-0555 hinges on several factors:

  • Prevalence of target condition: Epidemiological data suggest [statistics], supporting an estimated annual treatment need of [units].
  • Prescriber and patient adoption: Shifts in clinical guidelines, reimbursement policies, and physician preferences influence utilization rates.
  • Regulatory approvals: Expanded indications and label updates can accelerate market penetration.
  • Pricing behavior: Historically, the drug has been positioned as a premium-priced therapy owing to its therapeutic efficacy and manufacturing complexity.

Based on current sales data, the annual market size approximates [value in USD], with a compound annual growth rate (CAGR) of [percentage] over the past [period].


Pricing Trends and Historical Context

Market prices for NDC 00713-0555 have evolved driven by:

  • Reimbursement policies: Medicare and private insurers significantly influence net prices.
  • Manufacturing costs: Supply chain stability and raw material costs affect baseline pricing.
  • Patent and exclusivity status: Patent protections and market exclusivities typically sustain higher prices until patent cliffs or biosimilar entries.

Recently, list prices for the drug have been around $[amount] per [dose/formulation], with net prices often discounted by insurers and pharmacy benefit managers (PBMs). The introduction of biosimilars or generics could enforce downward pricing pressure, yet manufacturer strategies such as value-based pricing and patient assistance programs can mitigate this trajectory.


Factors Influencing Future Price Projections

Several elements will shape the future pricing of NDC 00713-0555:

  1. Patent and Exclusivity Timeline: Patent expiry in [year] could introduce biosimilars/genetics, reducing pricing power.
  2. Regulatory Developments: Additional approvals or label expansions could augment demand and sustain prices.
  3. Market Penetration of Competitors: The entry of cheaper alternatives will threaten premium pricing.
  4. Reimbursement Trends: Shifts towards value-based care and tighter insurer policies may pressure prices downward.
  5. Manufacturing and Supply Chain: Cost efficiencies and potential supply disruptions can cause price volatility.

Given these dynamics, analysts project:

  • Short-term (1-2 years): Stable or modest decrease in prices, with list prices holding around $[amount].
  • Medium-term (3-5 years): Potential decline of [percentage]%, contingent on biosimilar market entry and regulatory shifts.
  • Long-term (5+ years): Prices could stabilize at [lower amount/percentage] below current levels if biosímilar adoption accelerates.

Market Entry Risks and Opportunities

Opportunities include:

  • Enhanced formulation or delivery methods that improve patient adherence.
  • Strategic partnerships with biosimilar manufacturers.
  • Expanded indications to broaden market scope.

Risks encompass:

  • Patent litigation delaying biosimilar entry.
  • Pricing pressures from increased competition.
  • Regulatory hurdles impacting approval timelines.

The manufacturer’s strategic positioning will significantly influence pricing resilience.


Implications for Stakeholders

  • Payers need to prepare for dynamic pricing scenarios, optimizing formulary placements and negotiating value-based agreements.
  • Pharmaceutical companies should monitor patent landscapes and biosimilar developments to inform pricing strategies.
  • Patients may face fluctuating out-of-pocket costs depending on insurer negotiations and formulary status.

Conclusion

NDC 00713-0555 operates within a complex interplay of clinical efficacy, regulatory protections, competitive pressures, and evolving reimbursement models. Its future pricing trajectory will depend heavily on patent status, market competition, and payer strategies. While current prices reflect high demand and limited competition, impending biosimilar approvals are poised to exert downward pressure, necessitating proactive adaptation by stakeholders.


Key Takeaways

  • The drug's current market position benefits from patent protections and significant therapeutic demand.
  • Prices are expected to stabilize short-term, with potential declines as biosimilars enter the market.
  • Competitive pressures and regulatory changes are primary risk factors influencing future pricing.
  • Strategic partnerships and indication expansions offer opportunities for sustained revenue.
  • Payers will need to adapt formulary strategies to accommodate evolving market dynamics.

FAQs

1. When is the patent for NDC 00713-0555 expected to expire?
The patent is projected to expire in [year], after which biosimilar competition could emerge, impacting prices.

2. Are biosimilars available for this drug?
As of now, [yes/no], with biosimilar development underway or pending regulatory approval.

3. How will biosimilar entry affect the drug's price?
Biosimilar entry typically drives prices downward through competition, potentially reducing list prices by [percentage]% or more.

4. What is the primary driver of the drug’s current high price?
High research and development costs, limited competition, and its status as a specialized therapy contribute to premium pricing.

5. How can payers manage future costs associated with this drug?
Payers can negotiate value-based agreements, prioritize formulary management, and encourage use of biosimilars once available.


References

[1] Industry reports and market data sources.
[2] FDA product approval and patent information.
[3] Recent publications on biosimilar developments.
[4] Healthcare policy publications detailing reimbursement trends.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.